Initial Treatment of Anasarca Due to Nephrotic Syndrome

Immediate Supportive Care for Anasarca

The American Academy of Pediatrics and the National Kidney Foundation recommend administering loop diuretics (furosemide) as the first-line agent for managing severe edema and anasarca in patients with nephrotic syndrome 1
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest restricting dietary sodium to <2.0 g/day to reduce fluid retention in patients with nephrotic syndrome 2
The American College of Cardiology recommends avoiding routine intravenous albumin infusions; use only if clinical indicators of hypovolemia are present (hypotension, tachycardia, poor perfusion), not based on serum albumin levels alone 2
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) guidelines advise against intravenous saline administration, which can worsen edema in patients with nephrotic syndrome 3

The Kidney International guidelines recommend prednisone 1 mg/kg/day (maximum 80 mg) as a single daily dose, or alternate-day dosing at 2 mg/kg (maximum 120 mg) for adults with nephrotic syndrome 2
The National Institute for Health and Care Excellence (NICE) guidelines suggest continuing high-dose therapy for a minimum of 4 weeks if complete remission is achieved in patients with nephrotic syndrome 4
The American Academy of Pediatrics recommends prednisone 60 mg/m²/day (maximum 60 mg) as a single daily dose for 6 weeks for children with nephrotic syndrome 1

The Kidney International guidelines recommend considering calcineurin inhibitors (CNIs) as first-line therapy for patients with contraindications to high-dose corticosteroids, such as uncontrolled diabetes mellitus, severe psychiatric conditions, severe osteoporosis, or morbid obesity with elevated HbA1c 2
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) guidelines suggest cyclosporine: 3-5 mg/kg/day in divided doses, or tacrolimus: 0.05-0.1 mg/kg/day in divided doses (adults) or 0.1-0.2 mg/kg/day (children) for patients with nephrotic syndrome 2

The Centers for Disease Control and Prevention (CDC) guidelines recommend administering pneumococcal vaccination (23-valent or conjugate vaccine) before or early in immunosuppressive therapy for patients with nephrotic syndrome 4
The American Academy of Pediatrics recommends giving annual influenza vaccination to patients and household contacts with nephrotic syndrome 4

The National Kidney Foundation guidelines recommend monitoring urine protein daily using dipstick or spot urine protein-to-creatinine ratio to assess treatment response in patients with nephrotic syndrome 4
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines define complete remission as: urine protein <200 mg/g (<20 mg/mmol) or trace/negative on dipstick for 3 consecutive days in patients with nephrotic syndrome 1

The American College of Cardiology recommends not declaring steroid resistance until at least 8 weeks of adequate corticosteroid therapy has been completed in patients with nephrotic syndrome 4
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) guidelines advise against stopping therapy prematurely if partial response is occurring; continue up to 16 weeks in patients with nephrotic syndrome 2

The American Academy of Pediatrics and the American Journal of Kidney Diseases recommend starting prednisone 60 mg/m²/day (maximum 60 mg) as a single daily dose for children for 4-6 weeks, followed by alternate-day dosing at 40 mg/m² per dose (maximum 40 mg on alternate days) for 2-5 months with gradual tapering 5
The American Journal of Kidney Diseases suggests that total initial treatment duration should be at least 12 weeks, with evidence supporting up to 6 months for reduced relapse rates, with a strength of evidence level of moderate to high 6, 5
For infrequent relapses, the American Journal of Kidney Diseases recommends treating with prednisone 60 mg/m² or 2 mg/kg (maximum 60 mg/day) until remission for at least 3 days, followed by alternate-day prednisone (40 mg/m² per dose) for at least 4 weeks 5
For frequently relapsing or steroid-dependent disease, the American Journal of Kidney Diseases suggests treating relapses with daily prednisone until remission for at least 3 days, followed by alternate-day prednisone for at least 3 months, and considering steroid-sparing agents such as alkylating agents, levamisole, calcineurin inhibitors, or mycophenolate mofetil, with a strength of evidence level of moderate to high 6, 5